Clinical Trial Search

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Objective Tumor Response — 0 participants

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: Event-free Survival After 12 Months — 78 percentage of participants

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants

Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV

Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants

Primary: Event-free Survival — 76 percentage of patient

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Objective Response Rate — 2; 0 Patients

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276

Primary: Progression-free Survival at 1 Year — 77 percentage of participants

Primary: 1-year Progression-free Survival — 31 Participants

Primary: ORR — 13 Participants

Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659

Primary: Progression Free Survival (PFS) — 6.6 months

Primary: Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 13…

Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants

Primary: Complete Remission — 10 participants

Primary: Clinical Response Rate — 2; 0; 1; 1 participants